Edition:
India

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

69.18USD
20 Jul 2018
Change (% chg)

$-1.67 (-2.36%)
Prev Close
$70.85
Open
$71.35
Day's High
$71.62
Day's Low
$68.58
Volume
27,676
Avg. Vol
32,834
52-wk High
$76.29
52-wk Low
$26.60

Latest Key Developments (Source: Significant Developments)

Ascendis Pharma Files For Potential Mixed Shelf Offering, Size Not Disclosed - SEC Filing
Thursday, 31 May 2018 

May 30 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP
Thursday, 21 Dec 2017 

Dec 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING.  Full Article

Ascendis Pharma A/S Q3 loss per share EUR 1.04
Friday, 17 Nov 2017 

Nov 16 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S reports third quarter 2017 financial results.Q3 loss per share EUR 1.04.Q3 earnings per share view EUR -0.74 -- Thomson Reuters I/B/E/S.  Full Article

Ascendis Pharma reports Q2 loss per share EUR 0.53
Thursday, 1 Sep 2016 

Ascendis Pharma A/S : Ascendis Pharma A/S reports second quarter 2016 financial results and provides business update . Q2 loss per share eur 0.53 . Qtrly revenue euro 1.1 million versus euro 1.9 million .Q2 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP

* ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP